Note: Descriptions are shown in the official language in which they were submitted.
CA 02158268 2001-04-11
WO 9a~2G702 PCT/US9a~o5233
-1-
N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL
SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR
THIOESTER:S) AS HYPERCHOLESTEROLEMIC AGENTS
BACKGROUND OF INVENTION
This invention relates to chemical compounds
having pharmacological activity, to pharmaceutical
compositions which include these compounds, and to a
pharmaceutical method of treatment. More particularly,
this invention concerns certain N-acyl sulfamic acid
esters (or thioesters), N-acyl sulfonamides, and
N-sulfonyl carbam.ic acid esters (or thioesters) which
inhibit the enzyme, acyl-coenzyme A:cholesterol
acyltransferase (ACAT), pharmaceutical compositions
containing theses compounds, and a method of treating
hypercholesterolemia and atherosclerosis.
The compounds of the instant invention show
increased chemical stability over those of United
States Patent No. 5,245,068.
In recent years the role which elevated blood
plasma levels of cholesterol plays in pathological
conditions in man has received much attention.
Deposits of cholesterol in the vascular system have
been indicated ae causative of a variety of
pathological conditions including coronary heart
disease.
Initially, studies of this problem were directed
toward finding therapeutic agents which would be
effective in lowering total serum cholesterol levels.
It is now known that cholesterol is transported in the
blood in the form of complex particles consisting of a
WO 94/26702 PCT/LTS94/05233
-2-
core of cholesteryl esters plus triglycerides and a
variety of types of protein which are recognized by
specific receptors. For example, cholesterol is '
carried to the sites of deposit in blood=vessels in the
form of low density lipoprotein cholesterol (LDL '
cholesterol) and away from such sites..o~' deposit by
high density lipoprotein cholesterolrt~F~L cholesterol).
Following these discoveries, thelsearch for
therapeutic agents which control serum cholesterol
turned to finding compounds which are more selective in
their action; that is, agents Which are effective in
elevating the blood serum levels of HDL cholesterol
and/or lowering the levels of LDL cholesterol. While
such agents are effective in moderating the levels of
serum cholesterol, they have little or no effect on
controlling the initial absorption of dietary
cholesterol in the body through the intestinal wall.
In intestinal mucosal cells, dietary cholesterol
is absorbed as free cholesterol which must be
esterified by the action of the enzyme, acyl-
CoA:cholesterol acyltransferase ~ACAT) before it can be
packaged into the chylomicrons which are then released
into the blood stream. Thus, therapeutic agents which
effectively inhibit the action of ACAT prevent the
intestinal absorption of dietary cholesterol into the
blood stream or the reabsorption of cholesterol which
has been previously released into the intestine through
the body's own regulatory action.
SZJMMARY OF THE INVENTION '
The present invention is directed to compounds of
Formula I below, methods for using the compounds of
Formula I, pharmaceutical compositions thereof, and
processes for preparing the compounds.
WO 94126702 .. ~ ~ ~ ~ ' PCTlUS94/05233
-3-
The first aspect of the invention is a compound of
Formula I
0 0
.. _ _II_ _II_ _
Rl X II I C Y R~ I
0 R
or a pharnnaceutically acceptable salt thereof wherein:
X and Y are selected from oxygen, sulfur and (CR'R")n,
wherein n is an integer of from 1 to 4 and R' and
R" are each independently hydrogen, alkyl, alkoxy,
halogen, hydroxy, acyloxy, cycloalkyl, phenyl
optionally substituted or R' and R" together form
a spirocycloalkyl or a carbonyl;
with the proviso at least one of X and Y is
-(CR'R")n- and with the further proviso when
X and Y are both (CR°R")n and R' and R" are
hydrogen and n is one, Rl and R2 are aryl;
R is hydrogen, a straight or branched alkyl of from
1 to 8 carbon atoms or benzyl;
Rl and RZ are each independently selected from
(a) phenyl or phenoxy each of which is
unsubstituted or is substituted with l to
5 substituents selected from
phenyl,
an alkyl group having from 1 to 6 carbon atoms and
which is straight or branched,
an alkoxy group having from 1 to 6 carbon atoms
and which is straight or branched;
phenoxy,
hydroxy,
fluorine,
chlorine,
bromine,
vitro,
trifluoromethyl,
WO 94/26702 _ ~ ~ ~ PCT/US94/05233
-4-
-COOH,
-COOalkyl wherein alkyl has from 1 to 4 carbon
atoms and is straight or branched,
-(CHZ)pNR3R4 wherein p is zero or one, and each of
R3 and R4 is selected from hydrogen or a
straight or branched aryl group having 1 to
4 carbon atoms ; ~ "'
(b) 1- or 2-naphthyl un~~stituted or substituted
with from 1 to 3 substituents selected from
phenyl,
an alkyl group having from 1 to 6 carbon atoms and
which is straight or branched,
an alkoxy group having from 1 to 6 carbon atoms
and which is straight or branched;
hydroxy,
phenoxy,
fluorine,
chlorine,
bromine,
nitro,
trifluoromethyl,
-COOH,
-COOalkyl wherein alkyl has from 1 to 4 carbon
atoms and is straight or branched,
- (CHz)pNR3R,~ wherein p, R3 and R,~ have the meanings
def fined above ;
(c) arylalkyl;
(d) a straight or branched alkyl chain having
from 1 to 20 carbon atoms and which is saturated or
contains from 1 to 3 double bonds; or
(e) adamantyl or a cycloalkyl group wherein the
cycloalkyl moiety has from 3 to 6 carbon atoms;
with the provisos:
(i) where X is (CHZ)n, Y is oxygen, and R1 is a
substituted phenyl, then RZ is a
substituted phenyl;
WO 94/26702 ~. ~ ~ ~ PCT/US94105233
-5-
(ii) where Y is oxygen, X is (CHZ)n, R2 is
phenyl or naphthyl, then R1 is not a
straight or branched alkyl chain; and
(iii) the following compounds are excluded:
X . Y R Rl RZ
CHZ O H (CHZ)2CH3 Ph
CH2 0 H CH3 Ph
CH2 0 H ~ ~,-Pr
Preferred compounds of the instant invention are
those of Formula I:
wherein Rl is phenyl or is phenyl disubstituted in
the 2,6-positions,
wherein RZ is phenyl or is phenyl disubstituted in
the 2,6-positions,
wherein each of R1 and RZ is phenyl,
wherein each phenyl is disubstituted in the
2,6-position,
wherein R1 is phenyl disubstituted in the
2,6-positions and RZ is phenyl trisubstituted in the
2,4,6-positions,
wherein R1 is 2,6-bis(1-methylethyl)phenyl and RZ
is 2,6-bis(1-methylethyl)phenyl or 2,4,6-tris(1-methyl-
ethyl)phenyl,
wherein one of Rl and RZ is the group
R5
-(CH2)t-i-(CH2)w-R~ ,
R6
wherein t is zero or 1 to 4; w is zero or 1 to 4
with the proviso that the sum of t and w is not greater
than 5; R5 and R6 are each independently selected from
WO 94/26702 215 $ 2 6 ~
- PCT/US94/05233
-6-
hydrogen or alkyl having from 1 to 6 carbon atoms, or
when R5 is hydrogen, R6 can be selected from the groups
defined for R~; and R~ is phenyl or phenyl substituted
with from 1 to 3 substituents selected from a straight
or branched alkyl group having from i,.~o,6 carbon
atoms, straight or branched alkoxy group having from
1 to 6 carbon atoms, phenoxy, hydrQicy~; fluorine,
chlorine, bromine, nitro, trifluoromethyl, -COON,
COOalkyl wherein alkyl has from 1 to 4 carbon atoms, or
-(CHZ)pNR3R4 wherein P, R3 and R,~ have the meanings
defined above.
Also preferred compounds of the instant invention
are those of Formula I wherein
X is oxygen, sulfur or (CR'R")n;
Y is oxygen, sulfur or (CR'R")n, with the proviso that
at least one of X or Y is (CR'R")n wherein n is an
integer of from 1 to 4 and R' and R" are each
independently hydrogen, straight or branched alkyl
of from 1 to 6 carbons, optionally substituted
phenyl, halogen, hydroxy, alkoxy, acyloxy,
cycloalkyl, or R' and R" taken together form a
carbonyl or a spirocycloalkyl group of from 3 to
10 carbons;
R is hydrogen;
R1 is phenyl optionally substituted, straight or
branched alkyl of from 1 to 10 carbon atoms,
cycloalkyl of from 3 to 10 carbon atoms;
RZ is phenyl optionally substituted, straight or
branched alkyl of from 1 to 10 carbon atoms,
cycloalkyl of from 3 to 8 carbon atoms, phenoxy
optionally substituted With the proviso that only
if X is (CR'R")n can Rl be optionally substituted
phenoxy and only if Y is (CR'R")n can RZ be
optionally substituted phenoxy, and With the
further proviso that at least one of Rl and RZ is
optionally substituted phenyl or phenoxy.
~WO 94/26702 ' PCT/US94/05233
~' 2158268
More preferred compounds of the instant invention
are those of Formula I wherein
X is oxygen;
Y is (CR'R")n wherein n is an integer of from 1 to 2;
R is hydrogen;
R1 is optionally substituted phenyl;
R2 is optionally substituted phenyl or phenoxy,
straight or branched alkyl of from 1 to
carbons, or cycloalkyl of from 3 to 10 carbons;
10 and
R' and R" are each independently hydrogen, straight or
branched alkyl of from 1 to 6 carbons, optionally
substituted phenyl, halogen, hydroxy, alkoxy,
acyloxy, cycloalkyl, or R' and R" taken together
form a carbonyl or a spirocycloalkyl.
The present invention also provides a
pharmaceutical composition for regulating plasma
cholesterol concentrations comprising a therapeutically
effective amount of one or more compounds of Formula I.
It further provides a method of treating
hypercholesterolemia and for treating atherosclerosis
comprising administering to a patient an effective
amount of one or more compounds of Formula I with a
pharmaceutically acceptable carrier.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of the present invention provide a
novel class of N-acyl sulfamic acid esters (or
thioesters), N-acyl sulfonamides, and N-sulfonyl
carbamic acid esters (or thioesters) which are ACAT
inhibitors, rendering them useful in treating
hypercholesterolemia and atherosclerosis.
WO 94/26702 2 1 ~ g 2 6 8
PCT/US94/05233
-8-
In Formula I above, illustrative examples of
straight or branched saturated hydrocarbon chains
having from 1 to 20 carbon atoms include methyl, ethyl, '
g-propyl, isopropyl, n-butyl, iso-butyl, tert-butyl,
~-pentyl, isopentyl, ~-hexyl, g-beptyl, ~-octyl, "
~-undecyl, ~-dodecyl, ~-hexadecy~~ 2,2-dimethyldodecyl,
2-tetradecyl, and ~-octadecyl groups.
Illustrative examples of straight or branched
hydrocarbon chains having from 1 to 20 carbon atoms and
having from 1 to 3 double bonds include ethenyl,
2-propenyl, 2-butenyl, 3-pentenyl, 2-octenyl,
5-nonenyl, 4-undecenyl, 5-heptadecenyl, 3-octadecenyl,
9-octadecenyl, 2,2-dimethyl-11-eicosenyl,
9,12-octadecadienyl, and hexadecenyl.
Straight or branched alkoxy groups having from
1 to 6 carbon atoms include, for example, methoxy,
ethoxy, ~-propoxy, ~-butoxy, and pentyloxy.
Illustrative examples of straight or branched
alkyl groups having from 1 to 6 carbon atoms as used in
Formula I include methyl, ethyl, _r~-propyl, isopropyl,
g-pentyl, ~-butyl, and tart-butyl.
Illustrative examples of cycloalkyl groups, as
used in Forrnula I, include cyclopentyl, cyclohexyl,
cyclooctyl, tetrahydronaphthyl, and 1- or 2-adamantyl.
Spirocycloalkyl groups are, for example,
spirocyclopropyl, spirocyclobutyl, spirocyclopentyl,
and spirocyclohexyl.
Illustrative examples of arylalkyl groups are:
benzyl, phenethyl, 3-phenylpropyl, 2-phenylpropyl,
4-phenylbutyl, 2-phenylbutyl, 3-phenylbutyl,
benzhydryl, 2,2-diphenylethyl, and 3,3-diphenylpropyl. '
Pharmaceutically acceptable salts of the compounds
of Formula I are also included as a part of the present
invention.
The base salts may be generated from compounds of
Formula I by reaction of the latter with one equivalent
~WO 94/26702 ~ PCTIUS94/05233
_g_
of a suitable nontoxic, pharmaceutically acceptable
base followed by evaporation of the solvent employed
for the reaction and recrystallization of the salt, if
required. ' The compounds of Forntula I may be recovered
from the base salt by reaction of the salt with an
aqueous solution of a suitable acid such as
hydrobromic, hydrochloric, or acetic acid.
Suitable bases for forming base salts of the
compounds of this invention include amines such as
triethylamine or dibutylamine, or alkali metal bases
and alkaline earth metal bases. Preferred alkali metal
hydroxides and alkaline earth metal hydroxides as salt
foziners are the hydroxides of lithium, sodium,
potassium, magnesium, or calcium. The class of bases
suitable for the formation of nontoxic,
pharmaceutically acceptable salts is well known to
practitioners of the pharmaceutical formulation arts.
See, for example, Berge SN, et al, J Pharm Sci
1977;66:1-19.
Suitable acids for fornting acid salts of the
compounds of this invention containing a basic group
include, but are not necessarily limited to acetic,
benzoic, benzenesulfonic, tartaric, hydrobromic,
hydrochloric, citric, fumaric, gluconic, glucuronic,
glutamic, lactic, malic, malefic, methanesulfonic,
pamoic, salicylic, stearic, succinic, sulfuric, and
tartaric acids. The acid addition salts are formed by
procedures well known in the art.
The compounds of the present invention may also
exist in different stereoisomeric forms by virtue of
the presence of asymmetric centers in the compound.
The present invention contemplates all stereoisomeric
forms of the compounds as well as mixtures thereof,
including racemic mixtures.
Further, the compounds of this invention may exist
. in unsolvated as well as solvated forms with
WO 94/26702 PCT/US94/05233
s
s
215~~68
- -10-
pharmaceutically acceptable solvents such as water,
ethanol and the like. In general, the solvated forms
are considered equivalent to the unsolvated forms for '
the purposes of this invention. ~-
Preferred compounds of the present invention are "
those wherein one of Rl and Rz isk'~~henyl, and more
preferably wherein one of Rl and R2 is substituted
phenyl, and still more preferably wherein one of R1 and
R2 is phenyl disubstituted in the 2,6-positions.
In one preferred embodiment both R1 and R2 are
phenyl disubstituted in the 2,6-positions. In another
preferred embodiment Rl is phenyl disubstituted in the
2,6-position and R2 is trisubstituted in the
2,4,6-positions.
In another preferred embodiment of the present
invention, R1 is 2,6-bis(1-methylethyl)phenyl; and RZ
is 2,6-bis(1-methylethyl)phenyl or 2,4,6-tris(1-methyl-
ethyl)phenyl.
Preferred compounds of Formula I include, but are
not limited to the following:
Sulfamic acid (phenylacetyl)-2,6-bis(1-methyl-
ethyl)phenyl ester,
Sulfamic acid[[2,4,6-tris(1-methylethyl)phenyl]-
acetyl-2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid[[2,6-bis(1-methylethyl)phenyl]
acetyl]-2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid [[2,4,6-tris(1-methylethyl)phenyl]-
acetyl-2,4,6-tris(1-methylethyl)phenyl ester,
Sulfamic acid[[2,6-bis(1-methylethyl)phenyl]-
acetyl]-2,4,6-tris(1-methylethyl)phenyl ester,
Sulfamic acid[adamantaneacetyl]-2,6-bis[1-methyl- '
ethyl)phenyl ester,
Sulfamic acid[[2,6-bis(1-methylethyl)phenyl]-
acetyl]-2,6-bis(1-methylethyl)phenyl ester-sodium salt,
Sulfamic acid[[2,4,6-tris(1-methylethyl)phenyl]-
acetyl]-2,6-bis(1-methylethyl)phenyl ester-sodium salt,
,",,WO 94/26702 , 215 8 2 6 8 PCT~S94105233
-11-
Sulfamic acid (decanoyl)-2,6-bis-(1-methylethyl)-
phenyl ester,
Sulfamic acid (dodecanoyl)-2,6-bis-(1-methyl-
ethyl)phenyl ester,
2,6-Bis'(1-methylethyl)-N-[[[2,4,6-tris(1-methyl-
ethyl)phenyl]methyl]sulfonyl]benzeneacetamide,
2,6-Bis(1-methylethyl)-N-[[[2,4,6-tris-
(1-methylethyl)phenyl]methyl]sulfonyl]benzeneacetamide-
sodium salt,
2,6-Bis(1-methylethyl)phenyl[[[2,4,6-tris-
(1-methylethyl)phenyl]methyl]sulfonyl]carbamate,
2,6-Bis(1-methylethyl)phenyl[[[2,4,6-tris-
(1-methylethyl)phenyl]methyl]sulfonyl]carbamate-sodium
salt,
Sulfamic acid (1-oxo-3,3-diphenylpropyl)-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid [2,6-dichlorophenyl(acetyl)]-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid [2,6-dichlorophenyl(acetyl)]-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid traps-[(2-phenylcyclopropyl)-
carbonyl]-2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid [2,5-dimethoxyphenyl(acetyl)]-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid [2,4,6-trimethoxyphenyl(acetyl)]-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid [2,4,6-trimethylphenyl(acetyl)]-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid [2-thiophenyl(acetyl)]-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid [3-thiophenyl (acetyl) ] -
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid [2-methoxyphenyl(acetyl)]-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid (oxophenylacetyl)-
2,6-bis(1-methylethyl)phenyl ester,
WO 94/26702 PCT/US94/05233
21~826~
-12-
Sulfamic acid [2-trifluoromethylphenyl(acetyl)]-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid (1-oxo-2-phenylpropyl)-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid (cyclopentylpheny3acetyl)-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid (cyclohexylacetyl)-
2,6-bistl-methylethyl)phenyl ester,
Sulfamic acid (diphenylacetyl)-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid (triphenylacetyl)-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid [(1-phenylcyclopentyl)carbonyl]-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl)-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid (1-oxo-2-phenylbutyl)-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid (cyclohexylphenylacetyl)-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid (1-oxo-2,2-diphenylpropyl)-
2,6-bis(1-methylethyl)phenyl ester,
Sul f ami c acid [ ( 9Ii- f luoren- 9 - y1 ) carbonyl ] -
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid (1-oxo-3-phenylpropyl)-
2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid [1-oxo-3-[2,4,6-tris(1-methylethyl)
phenyl]-2-propenyl]-2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid [1-oxo-3-[2,4,6-tris(1-methylethyl)
phenyl]propyl]-2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid [(acetyloxy)[2,4,6-tris(1-methyl- -
ethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl
ester,
Sulfamic acid [hydroxy[2,4,6-tris(1-methylethyl)-
phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester,
~WO 94/26702 _ 2 ~ ~ ~ ~ PCTIUS94/05233
-13-
Sulfamic acid [fluoro[2,4,6-tris(1-methylethyl)-
phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl)-
2,6-bis(1-methylethyl)phenyl ester sodium salt,
Sulfamic acid [[2,4,6-tris(1-methylethyl)phenoxy]-
acetyl]-2,6-bis(1-methylethyl)phenyl ester,
Sulfamic acid [[2,6-bis(1-methylethyl)phenoxy]-
acetyl]-2,6-bis(1-methylethyl)phenyl ester, and
Sulfamic acid [[2,4,6-tris(1-methylethyl)phenyl]-
acetyl]-2,6-bis(phenyl)phenyl ester.
As shown by the data presented below in Table 1,
the compounds of the present invention are inhibitors
of the enzyme acyl-CoA:cholesterol acyltransferase
(ACAT), and are thus effective in inhibiting the
esterification and transport of cholesterol across the
intestinal cell wall. The compounds of the present
invention are thus useful in pharmaceutical
formulations for the treatment of hypercholesterolemia
or atherosclerosis.
The ability of representative compounds of the
present invention to inhibit ACAT was measured using an
in vitro test more fully described in Field FJ,
Salone RG, Biochemica et Bionhysica, 1982;712:557-570.
The test assesses the ability of a test compound to
inhibit the acylation of cholesterol by oleic acid by
measuring the amount of radiolabeled cholesterol oleate
formed from radiolabeled oleic acid in a tissue
preparation containing rat liver microsomes.
The data appear in Table 1 where they are
expressed in ICSO values; i.e., the concentration of
test compound required to inhibit the activity of the
enzyme by 50%.
WO 94/26702 PCT/US94/05233
2158268
-14
TABLE 1
~I
Exampl a IC~o (ErM)
1 9.7
2 ~ 12
. 3 ~. 11
4 .' , 13
12
6 12
7 47
8 21
10 >5
11 >10
13 , 25
14 33
15 34
16 36
17 >50
1g 22
19 >50
20 >50
21 55 ,
22 50
23 12
24 26
25 7.2
26 28
27 12
28 6
2g 15
30 . 4.1
31 3.3
32 8.9
33 9.3
CA 02158268 2001-04-11
WO 94/26702 PCT/US94/05233
-15-
TABLE 1 (cont.)
LAI
Example ICSO (EiM)
34 7.7
35 8.9
36 22
37 16
38 31
3g 32
40 32
41 28
42 7
43 31
44 9.4
45 5.6
46 34
47 38
48 8.3
In one in vivo screen designated APCC, male
Sprague-Dawley rats (200 to 225 g) were randomly
divided into treatment groups and dosed at 4 PM with
either vehicle (CMC/Tween*) or suspensions of compounds
in vehicle. The normal chow diet was then replaced
with a high fat, high cholesterol diet (designated PCC)
containing 0.5~ cholic acid. The rats consumed this
diet ad libitum during the night and were sacrificed at
8 AM to obtain blood saatples for cholesterol analysis
using standard procedures. Statistical differences
between mean cholesterol values for the same vehicle
were determined using analysis of variance followed by
Fisher's least significant test. The results of this
trial for representative compounds of the present
invention appear in Table 2.
* Trade-mark
WO 94126702 PCT/LTS94/05233
X158268
-16
TABLE 2
Compound of ~ Change .
Example (mg/dl?
1 .- 6 3
2 ;1..,'' -62
~'~
3 - 79
;..,. .
4 ~ -47
5 -73
6 -75
7 -17
8 -66
10 -26
11 -8
12 -5
13 -31
14 -12
15 -14
16 +10
17 -40
18 -47
19 -20
20 . -19
21 -16
22 -23
23 -19
24 -24
25 -71
26 -26
27 -72
28 -30
29 -9
30 -40
31 -30
32 -48
WO 94/26702 PCT/LTS94/05233
-17-
TABLE 2 (cont.)
Example ~ Change
(mg/dl)
33 -63
34 -67
35 -9
36 -6
37 -50
38 -16
39 +5
40 -54
41 -73
42 -25
43 -45
44 -74
45 -63
46 -57
47 -46
48 -73
In therapeutic use as agents for treating
hypercholesterolemia or atherosclerosis, the compounds
of Formulas I or II or pharmaceutically acceptable
salts thereof are administered to the patient at dosage
levels of from 250 to 3000 mg per day. For a normal
human adult of approximately 70 kg of body weight, this
translates into a dosage of from 5 to 40 mg/kg of body
weight per day. The specific dosages employed,
however, may be varied depending upon the requirements
of the patient, the severity of the condition being
treated, and the activity of the compound being
employed. The determination of optimum dosages for a
particular situation is within the skill of the art.
WO 94/26702 21 ~ 8 2 6 ~ PCT/US94/05233
-18-
For preparing the pharmaceutical compositions from
the compounds of this invention, inert, pharmaceu-
tically acceptable carriers can be either solid or
liquid. Solid forni preparations include powders,
~x
tablets, dispersible granules, capsules, and cachets.
A solid carrier can be one o~~inore substances
which may also act as diluents, lf~avoring agents,
solubilizers, lubricants, suspending agents, binders,
or tablet disintegrating agents; it can also be an
encapsulating material.
In powders, the carrier is a finely divided solid
which is in a mixture with the finely divided active
component. In tablets, the active component is mixed
with the carrier having the necessary binding
properties in suitable proportions and compacted in the
shape and size desired.
Powders and tablets preferably contain between
about 5% to about 70% by weight of the active
ingredient. Suitable carriers are magnesium
dicarbonate, magnesium stearate, talc, lactose, sugar,
pectin, dextrin, starch, tragacanth, methyl cellulose,
sodium carboxymethyl cellulose, a low-melting wax,
cocoa butter, and the like.
The term "preparation" is intended to include the
formulation of the active compound with encapsulating
material as a carrier providing a capsule in which the
active component (with or without other carriers) i$
surrounded by a carrier, which is thus in association
with it. In a similar manner cachets or transdermal
systems are also included.
Tablets, powders, cachets, and capsules can be
used as solid dosage forms suitable for oral
administration.
Liquid form preparations include solutions,
suspensions, or emulsions suitable for oral
administration. Aqueous solutions for oral
CA 02158268 2001-05-16
WO 94126702 . PCT/US94/05233
-19-
administration c:an be prepared by dissolving the active
compound in water and adding suitable flavorants,
coloring agents, stabilizers, and thickening agents as
desired. Aqueous suspensions for oral use can be made
by dispersing th.e finely divided active component in
water together with a viscous material such as natural
or synthetic gums, resins, methyl cellulose, sodium
carboxymethylcellulose, and other suspending agents
known to the pharmaceutical formulation art.
Preferably, the pharmaceutical preparation is in
unit dosage form. In such form, the preparation is
divided into unit doses containing appropriate
quantities of the active component. The unit dosage
form can be a packaged preparation containing discrete
quantities of the preparation, for example, packeted
tablets, capsules, and powders in vials or ampoules.
The unit dosage form can also be a capsule, cachet, or
tablet itself, or it can be the appropriate number of
these packaged forms.
Some of the preferred compounds of the present
invention are prepared as set forth in Chart I hereof
wherein R, R1 anc3 RZ have the meanings defined in
Formula I; and Z represents a halogen.
In Route 1, a solution of a halide of the
Formula RZZ in ether is added to a suspension of
Li powder in etha_r heated under reflex. The solution
is cooled to 0°C. The resulting lithium compound is
then poured into the liquid ethylene oxide precooled to
-78°C. The mixture is allowed to warn up to room
temperature. After work-up with saturated NH,~C1, the
product (3) is e:~ctracted with ethyl acetate. The
alcohol (3) is o:Kidized to the acid (4) by Jones
reagent (R2Cr20~/Fi2S04 ) in acetone at 0°C.
CA 02158268 2001-05-16
-19a-
Alternatively, the acid (4) can be arrived at using a
method similar to "Organic Synthesis", 1955, Ed. E.C.
Horning, Collective Volume 3, pages 559-568 (John Wiley &
Sons, Inc.) in which a~ substituted benzene is
chloromethylated
WO 94/26702 ~ ~ ~ PCT/US94/05233
-20-
followed by replacement of the chlorine with nitrile
and subsequent hydrolysis of the nitrile to the .
acid ( 4 ) .
The acid (4) is then allowed to xeact with oxalyl
chloride in toluene at room temperature to give acyl
chloride (5). Meanwhile, alcohol :(8) is treated with
chlorosulfonyl isocyanate in refluxing toluene to give
Compound 7, which is then hydrolysed with water to give
Compound 8. Compounds 5 and 8 are then mixed in THF in
the presence of Et3N at room temperature to give
Compound 9. In Route 1A, Compound 9 is also obtained
by reacting Compound 7 with R2CH2MgZ (15) (commercially
available or easily prepared through methods generally
known in the art) in THF under reflux. Compound 28 is
obtained by subsequently treating Compound 9 (as
arrived at by either Route 1 or 1A) with base and then
RZ.
Other compounds of the present invention are
prepared as set forth in Chart II (Routes 2 and 3),
hereof wherein R, R1 and R2 have the meanings defined
in Formula I; and Z represents a halogen.
In Route 2, a solution of halide (R1CH2Z) (14) and
thiourea (Compound 24) in absolute ethanol was heated
under reflux to give an isothiourea (R1CH2-
S-C(NH)NHZ) (25). Chlorine gas was bubbled through a
suspended solution of the isothiourea in HZO at 0°C,
followed by NH3~g~ to give the sulfonamide
(R1CH2SOZNHz) (18). Condensation between the
sulfonamide (18) and an acyl chloride (RZCH2COC1) (5)
in THF under NZ in the presence of Et3N gives an N-acyl
sulfonamide (Compound 21). Compound 18 is also allowed
to react with Compound 22 (see Route 3 for preparation
of Compound 22) in THF in the presence of Et3N at room
temperature to give Compound 23. Compound 28 is
obtained by subsequently treating Compounds 21 or 23
WO 94/26702 PCTIUS94/05233
-21-
(as arrived at by Routes 2 or 3, respectively) with a
base and then RZ.
The halides RZ, R2Z, and R1Z used in preparing the
compounds of this invention are known in the art or
prepared by procedures generally known in the art.
Whereas' the preferred compounds of the present
invention are prepared as set forth in Charts I and II,
it should be understood that the compounds of the
present invention can be prepared as set forth
generally as follows.
N-acyl sulfamic acid esters (or thioesters) having
the formula of Compound 9 in Chart I Route 1 can be
prepared by reacting an acyl chloride and a sulfamate
having the formula of Compounds 5 and 8, respectively,
in Route 1. The resulting ester (or thioester) can
optionally be reacted With a base, followed by an aryl
halide.
Alternatively, N-acyl sulfamic acid esters (or
thioesters) having the formula of Compound 9 in Chart I
Route 1A can be prepared by reacting an oxysulfonyl
isocyanate and a grignard agent having the formula of
Compounds 7 and 15, respectively, in Route 1A. The
resulting ester (or thioester) can optionally be
reacted with a base, followed by an aryl halide.
2 5 N- acyl sul f onamides having the f ornula of
Compound 21 in Chart II Route 2 can be prepared by
reacting an acid chloride and a sulfonamide having the
formula of Compounds 5 and 18, respectively, in
Route 2. The resulting sulfonamide can optionally be
reacted With a base, followed by an aryl halide.
N-sulfonyl carbamic acid esters (or thioesters)
having the formula of Compound 23 in Chart II Route 3
can be prepared by reacting a sulfonamide and a
chloroforn~a.te having the fornula of Compounds 18
and 22, respectively, in Route 3. The resulting ester
WO 94/26702 PCT/US94105233
218268
-22-
(or thioester) can optionally be reacted with a base,
followed by an aryl halide.
EXAMPLES _° ~_.,
w.'.:,
The following examples illustrate techniques
discovered by the inventors for the preparation of the
compounds of the present invention. It should be
appreciated by those of skill in the art that the
techniques disclosed in the examples which follow
represent laboratory techniques discovered by the
inventors to function well in the practice of the
invention, and thus can be considered to constitute
preferred modes for this practice. Those of skill in
the art should, however, in light of the present
disclosure, appreciate that many changes can be made in
the specific embodiments which are disclosed and still
obtain a like or similar result without departing from
the spirit and scope of the invention. In other words,
the following examples are given to illustrate
particular compositions and methods within the scope of
the present invention and are not intended to limit the
scope of the present invention.
EXAMPLE 1
~~~~~-hesis of sulfa_m~ acid W 2 6-bis m-meLnvieznv~. a -
phenvllacetyll-2 6-bisll-methvlethvl)vh~nvl ester
(a) ~ ~ Diisogrog~lphenvlethanol
2,6 diisopropylbromobenzene (see ~. Org. Chem.,
X2,(14) :2426-2431 (1977) for preparation) (30 g,
124.4 mmol) was added to a suspension of Li powder
(1.9 g, 273.6 mmol) in ether (100 mL) heated under
reflux, the heating was continued for another 4 hours,
cooled, and the mixture was poured into ethylene oxide
which was precooled to -78°C. The mixture was warmed
WO 94/26702
PCT/US94105233
-23-
slowly to room temperature, saturated NH4C1 solution
was added slowly with caution, the ether layer Was
separated and washed with brine, dried over MgS04,
filtered, and the solvent was evaporated to dryness.
After column chromatography (3:1 hexane: ethyl acetate)
pure 2,6-diisopropylphenylethanol was obtained (17 g,
66.3%);
NMR (CDC13): 8 1.2-1.3 (m, 12H), 3.05 (t, 2H),
3.15-3.35 (m, 2H), 3.7-3.8 (t, 2H), 7.1-7.3 (m,
3H) ppm.
(b) 2,6-Diisoprogylacetic acid
Jones reagent (94 mL, 2 M, 188 mmol) was added to
a solution of 2,6-diisopropylphenylethanol (19.2 g,
93.05 mmol) in acetone (600 mL) at 0°C over 2 hours.
The mixture was stirred for another 0.5 hour. The
reaction mixture was poured into ether (1 L), washed
with brine, and the product was extracted by 1N NaOH.
The basic extract was acidified with concentrated HC1,
the liberated acid was removed by ether extraction
(200 mL x 5). The combined ether extract was dried
over MgSO,~, filtered, and then evaporated. The residue
was used for the next step without further purification
(18.47 g, 90%);
NMR (CDC13): 8 1.15-1.35 (m, 12H), 3.05-3.25 (m, 2H),
3.85 (s, 2H), 7.1-7.35 (m, 3H) ppm.
(c) 5ulfamic acidff2.6-bis(1-methylethyl)phenyll-
acetyll-2.6-bis(1-methylet 1)phenyl ester
2,6-Diisopropylacetic acid (200 mg, 0.91 mmol) and
oxalyl chloride (253.9 mg, 2 mmol) were mixed together
in 20 mL of toluene at room temperature under N2 with a
few drops of DMF as catalyst. The mixture was stirred
for 16 hours, the solvent and the excess oxalyl
chloride were then removed in vacuo, and the acyl
chloride was redissolved in 20 mL of dry THF.
WO 94/26702 PCT/US94/05233
2158268
-24-
2, 6-Diisopropylphenyl sulfamate (257 mg, 1 nanol, see
phos. and Sulf., x:167 (1984) for preparation) and
Et3N (139 ~cL, 1 mmol) were added to the solution under
N2 and the mixture was stirred at room temperature for
3 hours. The solvent was removed~~and the residue was
distributed between ethyl acetate~~and 1N HC1. The
organic layer was dried over MgSO,~, filtered, and
evaporated, and the pure product was isolated by column
chromatography (1:1 hexane:EtOAc, 300 mg, 72~),
mp 166-168°C.
EXAMPLE 2
,~rnthPsis of sulfamic acid C f2 6-bis (1-methylethyl)
Sri t ac~Ar3ri 1 -2 , 6-bis (1-methvlethyl) Shenyl ester
Sodium salt
The sodium salt of the title compound of Example 1
was prepared by dissolving the title compound of
Example 1 (1 g, 2.18 mmol) in THF (10 mL), and one
equivalent of NaH (87 mg, 2.18 Col) was added to the
solution and this was then stirred for 0.5 hour. The
solvent was evaporated and product was obtained by
trituration with hexane (0.63 g, 60~), mp 242-244°C.
EXAN~LE 3
,synthesis of sulfamic acidff2 6-bis(1-methylethyl)-
g~yila~Pryit-2 4 6-tris(1-methylethyl)phenyl eater
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisoproplyphenyl sulfamate was replaced with
2,4,6-triisoproplyphenyl sulfama.te, mp 152-155°C.
EXAMPLB 4
,~~rnthPa;s of sulfamic acidfadamantaneacetyll-2.6-bis-
j~-methylethyllgheny'1 ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
WO 94/26702 PCTlUS94/05233
-25-
2,6-diisopropylphenylacetyl chloride was replaced with
adamantaneacetyl chloride;
1H NMR(CDC13): 1.21 (d, 12H), 1.6-2.0 (m, 15H),
2.15 (s, 2H),, 3.4 (m, 2H) , 7.15-7.25 (m, 3H) ppm.
EXAMPLE 5
Svnthes?s of Sulfamic acidff2.4.6-tris(1-methylethyl)-
ohenvl 1 acetvl l -2. 6-bis (1-methyleth3~3r1 ester
(a) 2.4.6-Triisop~~ylbenz~ri alcohol
. A solution of commercially available 2,4,6-triiso-
propylbenzoyl chloride (35 g, 131.2 mmol) in 400 mL
ether was added slowly to a suspension of lithium
aluminum hydride (LAH) (4.89 g, 131.2 mmol) in ether
(300 mL) at -15°C. The mixture was slowly warmed to
room temperature over 18 hours. Saturated Na2S04
solution was added slowly and the ether layer was
separated, dried over MgSO,~, and evaporated to dryness.
The compound was used in the next step without further
purification;
NMR (CDC13) : b 1.2-1.4 (m, 18H) , 2.8-3.0 (m, 1H) ,
3.3-3.5 (m, 2H), 4.8 (s, 2H), 7.1 (s, 2H) ppm.
(b) 2.4.6-Triisop~py~ben wi bromide
A solution of PBr3 (2.7 g, 10 mmol) in ether
(10 mL) was added slowly to a solution of 2,4,6-triiso-
propylbenzyl alcohol (4.68 g, 20 mmol) in 20 mL of
ether at room temperature. The mixture was stirred for
1 hour, 5 mL of absolute EtOH was added, and stirring
was continued for another 0.5 hour. The solvent was
removed and the residue distributed between EtOAc and
saturated Na2C03. The EtOAc layer was separated,
washed with brine, and dried over MgS04. The solvent
was evaporated and the pure product was isolated by
column chromatography (100 CH2C12, 3.5 g, 59~);
NMR (CDC13): 8 1.2-1.4 (m, 18H), 2.8-3.0 (m, 1H),
3.2-3.45 (m, 2H), 4.7 (s, 2H), 7.04 (s, 2H) ppm.
WO 94/26702 r ~ ~ PCT/US94/05233
-26-
(c) S"' fu.;.ic acid (2 4 6-tris (1-methylethyl) enyll
acetyi)2 6-b~s(~-methylethyl)rhenyl ester
A solution of 2,4,6-triisopropylbenzyl bromide
(12 g, 40.4 mmol) in dry THF (160 mL) was added to a
suspension of Mg powder (1.96'~g, 80.8 mmol) (4 hours)
in THF (20 mL) heated under reflex. 2,6-Diisopropyl-
phenoxysulfonyl isocyanate (ROSOZNCO) (see ,mhos. and
Su~.f . , x:167 (1984) for preparation) (11.45 g,
40.4 mmol) was added neat, and after the addition was
completed, the reflex was continued for another
2 hours. The reaction was stirred at room temperature
for 16 hours. Saturated NH~C1 and EtOAc were added.
The EtOAc layer was separated, dried over MgS04,
filtered, and evaporated to dryness. After
purification by column chromatography (4:1
hexane:EtOAc), the compound was isolated as white solid
(13.5 g, 67~), mp 178-180°C.
EXAMPLE 6
phenyll acet~ri t -2 6-bis (1-methyleth3rl) ohenvi ester
;sodium salt
This compound Was prepared in the same manner as
for the title compound of Example 2, except that the
title compound of Example 1 was replaced with the title
compound of Example 5, mp 250-252°C.
EXAMPLE 7
~kmthA~is of sulfamic acid(~he~vl_ acetyl)-2 6-bis-
~'-methylethyl)Bhenyl ester
This compound was prepared in the same manner as
the title compound of Example 5, except that
2,4,6-triisopropylbenzyl magnesium bromide was replaced
with benzylmagnesium chloride (commercially available),
mp 150-152°C.
WO 94/26702 PCT/US94/OS233
-27-
EXAMPLE 8
8yxithesis of sulfamic acid( f2.4. 6-tris (1- methvlet~rl) -
~yll acetyl 1 -2.4. 6-tris (1-methylet yl)rhenyl ester
This compound was prepared in the same manner as
the title compound of Example 5, except that 2,6-diiso-
propylphenoxy sulfonyl isocyanate was replaced with
2,4,6-triisopropylphenoxy sulfonyl isocyanate,
mp 178-180°C.
EXAMPLE 9
Synthesis of 2.6-Bis(1-methvlet~vl)-N-fff2.4.6-tris-
(1-methylethyl)phenyllmethvllsulfonvllbenzeneacetamide
(a) 5-2.4.6-Triisopropylbenz~ylisothiourea
A mixture of 2,4,6-triisopropylbenzyl bromide
(6.0 g, 20 mmol) and thiourea (1.536 g, 20.1 mmol) in
180 mL of absolute EtOH was heated under reflex for
3 hours. The reaction was cooled and evaporated. The
white powder (7.1 g, 95~) was used for next step
without further purification, mp 200-205°C.
(b) 2.4,6-Triisoprowlbenzylsulfonamide
Chlorine gas was bubbled through a suspension of
S-2,4,6-triisopropylbenzylisothiourea hydrobromide
(2.5 g, 8.56 mmol) in H20 (100 mL) at 0°C for 1 hour.
The solid was extracted into EtOAc (50 mL) and NH3(g)
was bubbled through the BtOAc solution at 0°C for
0.5 hour and the solution Was further stirred at room
temperature for 2 hours. 2,4,6-Triisopropylbenzyl-
sulfonamide was isolated as white powder (100 mg) by
column chromatography (4:1 hexane:EtOAc);
NMR (CDC13): b 1.2-1.6 (m, 18H), 2.8-3.0 (m, 2H),
3.25-3.4 (m, 2H), 4.75 (s, 2H), 7.0 (s, 2H), ppm.
WO 94/26702 PCTIUS94/05233
X158268
-28-
(c) 2 6-His (1-methylethvl~ -N- ( «2.4. 6-tris (1-methvl-
ethy ~phenY~ 1 methyl l sui fon~~? 7 benze eaceta_m? de
A solution of 2,4,6-triisopro~ylbenzylsulfonamide
(100 mg, 0.33 mmol), 2,6-diisopropylphenylacetyl
chloride (75 mg, 0.34 mmol) , _ai~~l Et3N (47 JCL,
0.34 mmol) in 10 mL THF was stirred at room temperature
overnight. The solvent was evaporated and the residue
was distributed between ethyl acetate and O.1N HC1, the
organic layer was washed with brine, dried, and
evaporated. The pure product (20 mg, 12~) was isolated
by column chromatography (4:1 hexane:EtOAc), m/e = 499;
NMR (CDC13): ~ 7.05-7.4 (m, 5H), 4.25 (s, 2H), 3.95
(s, 2H), 3.45-3.6 (m, 1H), 3.0-3.15 (m, 2H), 2.85-3.0
(m, 2H), 1.05-1.4 (m, 30H) ppm.
EXAMPLE 10
~th~~;s of sulfamic acid ldecanoyl)-2 6-bis-
-methylethyl ) ~h,~,nyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetyl chloride was replaced with
decanoyl chloride, mp 92-94°C.
EXAMPLE 11
l~ -met xlethy~phenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetyl chloride was replaced with
dodecanoyl chloride;
1H NMR (DMSO-26): 8 7.09 (s, 3H), 3.65 (heptet, 2H),
2.05 (t, 2H), 1.48-1.15 (m, 18H); 1.10 (d, 6H), 0.86
(t, 3H) ppm. '
WO 94/26702 PCTIUS94105233
-29-
EXAMPLE 12
synthesis of sulfamic acid (1-adamantvl (carbonyl) ) -
2.6-bis(1-methvlethyl)phenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced With
1-adamantecarboxylic acid, mp 165-167°C.
EXAMPLE 13
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
3,3-diphenylpropionic acid, mp 149-152°C.
EXAMPLE 14
S3rnthesis of sulfamic acid f2. 6-dichloroy~henvl (acetyl) 1 -
2.6-bis (1-meth5rlethyl)phenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
2,6-dichlorophenylacetic acid, mp 203-205°C.
EXAMPLE 15
~vnthesis of sulfamic acid traps-((2-nhenylcyclo-
pronyl ) carbonyl l -2 . 6 -bis ( 1-methvlethyl phenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
traps-2-phenylcyclopropylcarboxylic acid, mp 166-168°C.
WO 94/26702 PCT/US94/05233
2158268
-30-
EXAMPLE 16
~y_n_r_rAQ; a of sulfamic acid_f2. 5-dimethoxvnhenyl-
(a~Pry111-2 6-bis(1-methylethv~ phenyl ester
This compound was prepared in the same manner as
for the title compound of Exampl~erl, except that
2,6-diisopropylphenylacetyl chloride was replaced with
2,5-dimethoxyphenylacetyl cYi3~oride, mp 150-152°C.
EXAMPLE 17
~,y_rlthesis of sulfamic acid f2 4 6-trimethoxvnhenyl-
(~cPrylp -2.6-bis(1-methvlethyl)phenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
2,4,6-trimethoxyphenylacetic acid, mp 159-163°C.
EXAMPLE 18
$ynthes?s of sulfamic acidf2.4.6-trimethylShenyl-
Pr3r1 ) 1 -2 . 6 -bis ( 1-meth3rlethyl ) ~yl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
2,4,6-trimethylphenylacetic acid, mp 159-161°C.
ExAMPLE 19
~~;~.t.hes~ s of sulfamic acid f2-thiophenyl (acetyl) 1 -
2 6-bis(1-methylethyl)phenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
2-thiopheneacetic acid, mp 133-136°C.
WO 94/26702 ~ PCT/US94/05233
-31-
EXAMPLE 20
Synthesis of sulfamic acidf3-thio~henyl(acetyl)1-
2,6-bis(1-methylethyl)phenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
3-thiopheneacetic acid, mp 136-138°C.
EXAMPLE 21
2,6-bis(1-mett4ylethyl)rhenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
2-methoxyphenylacetic acid, mp 159-161°C.
EXAMPLE 22
Synthesis of sulfamic acid(oxo~heny acetvl)-
2.6-bis(1-methylethyl)~henyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
benzoylformic acid, mp 106-109°C.
EXAMPLE 23
Synthesis of sulfamic acid (2-trifluoraanethy ~,Shenyl-
(acetyl)l-2.6-bisll-methyleth~yl)nhenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
2-trifluoromethylphenylacetic acid, mp 144-149°C.
WO 94126702 PCT/US94/05233
2158268
-32-
EXAMPLE 24
~3~rr~~~;~ of sulfamic acid(1-oxo-2-y~henjrlrro
6-bis(1-methylethyl)phen~rl ester
This compound was prepared in°the same manner as
for the title compound of Example'~1, except that '
2,6-diisopropylphenylacetic acid was replaced with
2-phenylpropionic acid, mp 142-144°C.
SxAMPLE 25
~,y~th°°;~ ~f sulfamic acid(cyclopentyhhenvlacetvl)-
6-bis (1-methvlet y~,p~gyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
a-phenylcyclopentanecarboxylic acid, mp 142-143°C.
EXAMPLE 26
c acid l c
1)nhenvl
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
cyclohexylacetic acid;
1H NMR (CDC13): a 8.35 (s, 1H), 7.1-7.3 (m, 3H),
3.3-3.45 (m, 2H), 2.35 (d, 2H), 1.55-1.95 (m, 8H), 1.22
(d, 12H) , 0.9.-1.1 (m, 2H) , ppm.
EXAMPLE 27
,~1~~-hPsis of sulfamic acid(diphenylacety~
~-~-bis(1-methylethyl)1 ester
This compound was prepared in the same manner as '
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid Was replaced with '
diphenylacetic acid, mp 164-166°C.
WO 94/26702 PCT/US94/05233
-33-
EXAMPLE 28
~yntheai a of sulfamic acid (triphenylacetyl) -
2.6-bis(1-methylet 1)phenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
triphenylacetic acid, mp 142-144°C.
EXAMPLE 29
~-nab,hthyl)carbonyll-2.6-bis(1-methvlethyl)nhenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
1,2,3,4-tetrahydro-2-naphthoic acid, mp 137-139°C.
EXAMPLE 30
diathesis of sulfamic acidf(1-phenylcyclosentyl?-
carbonYll-2.6-bis(1-methylet yl)phenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
1-phenyl-1-cyclopentanecarboxylic acid, mp 149-152°C.
EXAMPLE 31
synthesis of sulfamic acid(3-methY~.-1-oxo-
2-~hen3rl~entyl)-2.6-bis(1-methylethyl)pheny1 ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
3-methyl-2-phenylvaleric acid;
1H NM12 (CDC13) : a 8.65 (bs, 1H) , 7.36-7.11 (m, 8H) ,
3.35-3.21 (m, 3H), 2.18 (bs, 1H), 1.73-0.69 (m, 20H),
PPm.
WO 94/26702 ~ PCT/LJS94/05233
-34-
EXAMPLE 32
synthesis of sulfamic acid(1-oxo-2-nhenvlbutvl)-
? 6-bis(1-methvlethy~phenvl ester '
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6- .diisopropylphenylacet~l; chloride was replaced with
2-phenylbutyryl chloride;vmp 142-145°C.
EXAMPLE 33
~y~th s~s of sulfamic acid(cvci~hP~lnhenvlacetyl)-
6-b~ s (1-met~,vlet y~o~vl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
cx-phenylcyclohexanecarboxylic acid, mp 127-137°C.
EXAMPLE 34
i 1- n _
6-bis(1-methvlethy~ghPnvl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
2,2-diphenylpropionic acid, mp 140-145°C.
EXAMPLE 35
h if i 4- r h
~ 6 bis(1-methy ethyl ghenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
bist4-chlorophenyl)acetic acid, mp 175-176°C.
WO 94/26702 ~ ~ ~ ~ PCTIUS94/05233
-35-
fiXAMPLE 36
,gynthes;s of sulfamic acidf(9H-xanthen-9-vl)carbonvll-
6-bis (1-methvlethvl)phenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
xanthene-9-carboxylic acid, mp 180-181°C.
EXAMPLE 37
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
9-fluorenecarboxylic acid, mp 146-147°C.
EXAMPLE 38
~~~nthes;s of sulfamic acid(1-oxo-3-phenvlnrovvl)-
6-bis(1-meth ethyl)8henyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
hydrocinnamic acid, mp 121-124°C.
EXAMPLE 39
of sulfamic acid (bromo (phenyl.) acetyll -
6-bis(1-methylethyl)phenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
a-bromophenylacetic acid, mp 155-159°C.
WO 94/26702 PCT/LTS94/05233
~l~g~,68
- -36-
EXAMPLE 40
~y"rhAQ;~ of sulfamic acidfl-oxo-3-f2.4.6-tris-
(1-meth~rl.et~y3lp.~I~y,~.) -2-y~roren~rll -2.6-bis- '
~ i -mPthyi Pr y~phen3rl ester
(a) 3-f2 4 6-tris(1-methylethyl)nhenyll-2-~ro~envl '
r~arhn~=i_r acid. meth3rl ester
A mixture of methyl acrylate (15.9 mL, 176 mmol)
and bis(triphenylphosphine)palladium (II) chloride
(0.99 g, 1.4 mmol) in 125 mL dimethylformamide and
125 mL triethylamine was heated to reflux for 1 hour
and then 2,4,6-triisopropylbromobenzene (10.0 g,
35 mmol) was added. Reflux was continued for 6 hours
and then stirred at room temperature for 16 hours.
Partitioned the reaction between water and diethyl
ether. The ether layer was dried with MgSO,~, filtered,
and concentrated to give a brown oil. Chromatography
(Si02, eluant ~ 5~C ethyl acetate in hexanes) gave
3.80 g of 3-[2,4,6-tris(1-methylethyl)phenyl]-
2-propenyl carboxylic acid, methyl ester as an off-
white solid, mp 61-63°C.
(b) ~,- f2 4 6-tris (1-methyl ethyllp~yl~urooenvl
GarbOX3",rlic acid
Sodium hydroxide (0.23 g, 5.7 mmol) was added to a
solution of 3-[2,4,6-tris(1-methylethyl)phenyl]-
2-propenyl carboxylic acid, methyl ester (1.5 g,
5.2 mmol) in 100 mL methanol and 10 mL water. Stirred
at room temperature for 48 hours and concentrated to
dryness. Partitioned the residue between water and
diethyl ether. The aqueous layer was acidified with
concentrated HC1 and extracted with dichloromethane.
The organic extract was dried over MgS04, filtered, and
concentrated to give 1.33 g of 3-[2,4,6-tris-
(1-methylethyl)phenyl]-2-propenyl carboxylic acid as a
white solid, mp 201-203°C.
WO 94!26702 PCT/US94/05233
-37-
(c) ~tzlfa_mi c acid (1-oxo-3- f2.4, 6-tris (1-methvlet~,~yl) -
~henvll -2-~ronenyll -2.6-bis (1-methvlet . lZ,phenvl
ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
3-[2,4,6-tris(1-methylethyl)phenyl)-2-propenyl
carboxylic acid, mp 144-148°C.
EXAMPLE 41
Svr~thesis of sulfamic acid 1-oxo-3-f2.4,6-tris-
(1-methvlethvl) uhenyll p~p3r1 1 -2 . 6-bis ll-met~rlethyl) -
phenyl ester
(a) 3- (2.4. 6-tris (1-methylethyl)phenyll",p,~sionic acid.
methyl ester
3-[2,4,6-tris(1-methylethyl)phenyl)-2-propenyl
carboxylic acid, methyl ester (2.20 g, 7.6 mmol, from
Example 40(a)) Was dissolved in 100 mL methanol. 0.5 g
of 20% palladium on carbon was added and the mixture
was charged with 50 psi of hydrogen gas. After 5 hours
at room temperature, the reaction was filtered and
concentrated to give 2.37 g of 3-[2,4,6-tris(1-methyl-
ethyl)phenyl)propionic acid, methyl ester as an off-
white solid, mp 45-47°C.
(b) 3- I2 4 6-tris (1-methylet ,y~pheny~sronionic acid
3-[2,4,6-Tris(1-methylethyl)phenyl)propionic acid,
methyl ester (2.12 g, 7.3 mmol) was dissolved in 100 mL
methanol and 10 mL water. Sodium hydroxide (0.32 g,
8.0 mmol) Was added and the resulting solution was
stirred at room temperature for 4 hours. Concentrated
in vacuo and partitioned the residue between water and
diethyl ether. The aqueous layer was acidified with
concentrated FiCl and extracted with dichloromethane.
The organic extract was dried over MgSO~, filtered, and
concentrated to give 1.87 g of 3-[2,4,6-tris(1-methyl-
WO 94/26702 PCT/US94/05233
X158268
-38-
ethyl)phenyl]propionic acid as a white solid,
mp 194-196°C.
";t
(c) Sulfamic acidfl-oxo-3- f2 4' 6'-tris(1-methvlethvl) -
p eny~y~rogv> > -2 6-bis (i-niethylethvllahenvl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
3-[2,4,6-tris(1-methylethyl)phenyl]propionic acid,
mp 138-141°C.
EXAMPLE 42
,synthesis of sulfamic acidf (acetyl, ox~r) f2.4.6-tris-
( 1 methylet y,~p~~yl ) - 2 6 -bis ( 1-meth~rlethvl ) -
phenyl ester
(a) Aeety~oxyf2 4 6-tris(1-methylethyl)ahenvllacetic
Glyoxylic acid (1.99 g, 27 mmol) and 1,3,5-triiso-
propylbenzene (5.0 g, 24.5 mmol) were mixed in 30 mL
glacial acetic acid and 2 mL conceatrated sulfuric
acid. The resulting solution was heated to reflux for
5 hours and then stirred at room temperature for
16 hours. The reaction mixture was poured into 100 g
ice and the resulting mixture was extracted with
diethyl ether. The organic layer was dried over MgS04,
filtered, and concentrated to give an oily solid which
was recrystallized from hexanes to give 3.29 g of
acetyloxy[2,4,6-tris(1-methylethyl)phenyl]acetic acid,
mp 166-169°C.
(b) r rar.Ar~rloxy) f2 ~ 6-tris (1-methylethyl)~envll
~~p~-yll -2 6-bis (1-met~lethyl)~yl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
WO 94/26702 w 2 y ~ g 2 ~ g PCTIUS94105233
-39-
acetyloxy[2,4,6-tris(1-methylethyl)phenyl]acetic acid,
mp 140-146°C.
EXAMPLE 43
Svnthesi s of sulfamic acid (~rdrnYy r~ a 6-tris-
(1-methv~y~prAnvi i a~ary~l -2 5-bis li-methylethylo
Shenyl. ester
[(Acetyloxy)[2,4,6-tris(1-methylethyl)phenyl]
acetyl]-2,6-bis(1-methylethyl)phenyl ester (1.50 g,
2.7 mmol) was dissolved in 75 mL methanol and 25 mL
water. Sodium hydroxide (0.22 g, 5.5 mmol) was added
and the resulting solution was stirred at room
temperature for 16 hours. Concentrated in vacuo,
redissolved the residue in water, acidified to pH 4.0
with concentrated HC1 and extracted with diethyl ether.
The organic extract was dried over MgSO,~, filtered, and
concentrated to give an oil. Triturated with hexanes
to give 0.56 g of sulfamic acid [hydroxy[2,4,6-tris-
(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)-
phenyl ester, mp 96-101°C.
EXAMPLE 44
Synthesis of sulfami~ acidfflLnrnr~ a ~-tris
(? -methvlethvl ) rrheny~ 1 acelGyi l -2 6-bis (1-meth~r et y1)
henyl ester
[Hydroxyl2,4,6-tris(1-methylethyl)phenyl]acetyl]-
2,6-bis(1-methylethyl)phenyl eater (0.73 g, 1.4 mmol)
was dissolved in 20 mL dichloromethane and added
dropwise to a solution of diethylaminosulfur
trifluoride (0.19 mL, 1.4 mmol) in 10 mL
dichloromethane at -8°C. Gradually warmed to room
temperature and stirred for 16 hours. Concentrated
in vacuo and partitioned the residue between water and
ethyl acetate. The organic extract was dried over
MgS04, filtered, and concentrated to give a yellow oil.
Triturated with hexanes to give 0.39 g of sulfamic acid
WO 94126702 PCTIU594105233
- -40-
[fluoro[2,4,6-tris(1-methylethyl)phenyl]acetyl]-
2,6-bis(1-methylethyl)phenyl ester, mp 130-132°C.
EXAMPLE 45
~~r~~hps~s of su famic acidt3-methyl-1-oxo-~-D~env~-
gentyl)-2 -6-bis(1-methylethyl)phenyl a ter sodium salt
This compound was prepared in the same manner as
for the title compound of Example 2, except that the
title compound of Example 1 was replaced with the title
compound of Example 3l, mp 275-277°C.
EXAMPLE 46
,~3rnth s~ s of sulfamic acid f f2 4 6-tris (1-methvlethvl? -.
p no lacetyll-2 6-bis(1-methylet~yl~henyl ester
(a) f2 4 6-tris(1-methvlethvl)g en liacetic acid
A solution of 2,4,6-triisopropylphenol (4.0 g,
18 mmol) in 50 mL tetrahydrofuran was added dropwise to
a suspension of sodium hydride (1.52 g, 38 mmol) in
mL tetrahydrofuran. The resulting pale green
20 suspension was stirred for 30 minutes before a solution
of bromoacetic acid (2.52 g, 18 mmol) in 50 mL
tetrahydrofuran was added dropwise. The resulting
thick suspension was stirred for 16 hours and then
concentrated in vacuo. The residue was partitioned
25 between 1N HC1 and dichloromethane, the organic extract
was dried over MgSO~, filtered, and concentrated to
give a yellow solid. Recrystallized from hexanes to
give 3.1 g of [2,4,6-tris(1-methylethyl)phenoxy]acetic
acid, mp 105-108°C.
(b) Sulfamic acidff2 4 6-tris(1-metl~ylethyl)uhenoxyl-
ar.ArYit-2 6-bis(1-methylethyl)phenyl ester
This compound was prepared in the same manner as '
for the title compound of Example 1, except that
2,6-diisopropylphenylacetic acid was replaced with
~WO 94!26702 -
PCT/US94/05233
-41-
[2,4,6-tris(1-methylethyl)phenoxy]acetic acid,
mp 126-128°C.
EXAMPLE 47
This compound was prepared in the same manner as
for the title compound of Example 46, except that
2,4,6-triisopropylphenol was replaced with
2,6-diisopropylphenol, mp 108-110°C.
EXAMPLE 48
synthesis of sulfamic acid(f2.4.6-tris(1-methylethyl)-
phenyll acetyl! -2 . 6-bis (phenyl)phen3rl ester
(a) 2.6-Bislphenzrl)phenyl sulfamate
A solution of chlorosulfonyl isocyanate (5.57 mL,
64 mmol) in 50 mL toluene was added dropwise to a
solution of 2,6-diphenylphenol (15.0 g, 61 mmol) in
200 mL toluene at 50°C. The resulting white suspension
was heated to reflex for 16 hours. Concentrated
in vacuo and carefully partitioned the residue between
water and diethyl ether. The ether layer was dried
over MgSO,~, filtered, and concentrated to give an off-
white solid. Recrystallized from hexanes to give
2,6-bis(phenyll)phenyl sulfamate as a white solid,
mp 145-147°C.
(b) Sulfamic acid f (2.4. 6-tris (1-methyleth3rl) phenyl? -
ace~yll-2.6-bis(phenyl)phenyl ester
This compound was prepared in the same manner as
for the title compound of Example 1, except that
2,6-diisopropylphenyl sulfamate was replaced With
2,6-bis(phenyl)phenyl sulfamate, mp 129-132°C.
WO 94/26702 PCT/US94105233
5~~6$
_42_
CHART I
(R, R1, and R2 have the meanings defined in Formula I;
and Z reg~esents a halogen) .
RoLte 1
RZZ R2Li -_=
R~CHzCHZOH
ether -78C
re flux
1
0
r
Jones ~~
R=CHZCO=H R
CH
Cl
Reagent toluene
C r.
acetone. O t
.
4
O O
O
2 0 a toluen; R10SNC0
HZO
R10SNH=
SNCO r~
R10H + Cl
~ O
O Z
o
O
I r
+ g oR1 use
NS
~ R2cH2c
Et3N
r.t. O
3
o
n
Ra~O 8~ ~Rl - R2~N~ yO.Ri
R Z-~-
~
v O O
N ~ I
R
45
WO 94/26702 ~ ~ PCTIUS94105233
T
-43
CHART I (continued)
(R, Rl, and RZ have the meanings defined in Formula I;
and Z represents a halogen)
10 ~ et~~er~ RZCHZOH e~ R2CHZZ ~ RZCH2MQZ
RZCC1
r.t. r.t.
I) 0 0
R10SNC0 + R2CHZMQZ re-~ R2CH~CNH~IOR1
I)
O ~ 0
25 0 0 0 00
Ba~ R2 " 'S' R_~ R2~N~~'O~Rl
~~ UO ORl v ' I O
R
35
45
WO 94/26702 PCT/LTS94/05233
-44
CHART I (continued)
(R, Rl, and RZ have the meanings defined in Formula I;
and Z represents a halogen)
Route 1B
BCOH, HC1 ~Cl
R ~ HOAC R
88~
KCN, DMSO 'CN
R
.31
Diethylene glycol R COZB
s
86~
4
40
50
WO 94/26702 PCT/LJS94/05233
_2I~8~68
-45
CHART II
(R, R1, and R2 have the meanings defined in Formula I;
and Z represents a halogen)
S
A1CHZZ + HyN"NHZ Et~ R1CH1_S-C~ .HZ
reflex NHy
O
1) C1=(Q) /H=0. 0'C R1~=~l ~ ~, R1CH~NCCH=Ri
s ) NH, cal . O C o off
1$ ?.Z
0 0 0~ $
Bass Rl~u'N~R= R-Z' R1~~~~Ri
OO'~/ O ~ vR
Z8.
H3C~N.CH3
O O
II
C1CC1 + R~OH o RsOCCl
Benzene, 0 C
O O
Hase
4 0 ~ + ~ Et~ N _, RiCgs ~ NHCOR?
THF, r.t.
O
O O O O
II ~ R-Z p
Rl~SwO O~R~ -.i. Ri~yN O~R~
O O I
R
